Adenine nucleotides and dinucleotides as new substances for the treatment of ocular hypertension and glaucoma

Current Opinion in Investigational Drugs

Volumn 6, Issue 1, 2005, Pages 76-80

  Pintor, Jesús ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Diadenosine; Glaucoma; Intraocular pressure; Nucleotide receptors; Ocular hypertension; Polyphosphates

Indexed keywords

ADENINE NUCLEOTIDE; ADENOSINE TETRAPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE DERIVATIVE; ALPHA,BETA METHYLENEADENOSINE TRIPHOSPHATE; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA,GAMMA METHYLENEADENOSINE TRIPHOSPHATE; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIADENOSINE POLYPHOSPHATE; DIADENOSINE TETRAPHOSPHATE; DINUCLEOTIDE; NUCLEOTIDE; PROSTAGLANDIN DERIVATIVE; PURINE P2X RECEPTOR; PURINE P2Y RECEPTOR; UNCLASSIFIED DRUG;

ACCOMMODATION; ANTIHYPERTENSIVE ACTIVITY; AQUEOUS HUMOR FLOW; AQUEOUS HUMOR FORMATION; CHOLINERGIC NERVE; DRUG DEGRADATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; GLAUCOMA; HUMAN; HYDRODYNAMICS; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NONHUMAN; OPTIC NERVE LESION; REVIEW; SIDE EFFECT; VISUAL IMPAIRMENT;

ADENINE NUCLEOTIDES; ANIMALS; DINUCLEOSIDE PHOSPHATES; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; RECEPTORS, PURINERGIC P2;

EID: 12544253963     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Davson H: The aqueous humour and the intraocular pressure. In: Physiology of the Eye. Pergamon Press, New York, NY, USA (1985) 5:3-95.
2. To CH, Kong CW, Chan CY, Shahidullah M, Do CW: The mechanism of aqueous humour formation. Clin Exp Optom (2002) 85(6):335-349.
3. Stone RA: Nervous system and intraocular pressure. In: The Glaucoma. Ritch R, Shields MB, Krupin T (Eds), Mosby, St Louis, Mo, USA (1996) 1:357-383.
4. Bergmanson JPG: Neural control of intraocular pressure. Am J Optom Physiol Opt (1982) 59(1):94-98.
5. Weinreb RN, Khaw PT: Primary open-angle glaucoma. Lancet (2004) 363(9422):1711-1720.
6. Lee WR: Doyne Lecture. The pathology of the outflow system in primary and secondary glaucoma. Eye (1995) 9(1 ):1-23.
7. Herkel U, Pfeiffer N: Update on topical carbonic anhydrase inhibitors. Curr Opin Ophthalmol (2001) 12(2):88-93.
8. Stamper RL, Wigginton SA, Higginbotham EJ: Primary drug treatment for glaucoma: β-Blockers versus other medications. Surv Ophthalmol (2002) 47(1):63-73.
9. Ritch R: The pilocarpine paradox. J Glaucoma (1996) 5(4):225-227.
10. Lindén C: Therapeutic potential of prostaglandin analogues in glaucoma. Expert Opin Investig Drugs (2001) 10 4):679-694.
11. Burnstock G: The past, present and future of purine nucleotides as signalling molecules. Neuropharmacology (1997) 36(9):1127-1139.
12. North RA: Molecular physiology of P2X receptors. Physiol Rev (2002) 82(4):1013-1067.
13. Sak K, Webb TE: A retrospective of recombinant P2Y receptor subtypes and their pharmacology. Arch Biochem Biophys (2002) 397(1):131-136.
14. 15, for AMP and adenosine. J Biol Chem (2004) 279 19):19790-19799.
15. Farahbakhsh NA: Purinergic signaling in the rabbit ciliary body epithelium. J Exp Zool (2003) 300(1):14-24.
16. Maul E, Sears M: ATP is released into the rabbit eye by antidromic stimulation of the trigeminal nerve. Invest Ophthalmol Vis Sci (1979) 18(3):256-262.
17. Pintor J, Peral A, Peláez T, Martín S, Hoyle CHV: Presence of diadenosine polyphosphates in the aqueous humor: Their effect on intraocular pressure. J Pharmacol Exper Ther (2003) 304 1):342-348.
18. 4, a physiological regulator of intraocular pressure in normotensive rabbit eyes. J Pharmacol Exp Ther (2004) 308(2):468-473.
19. 4), a new agonist on rat midbrain synaptic terminal P2 receptors. Neuropharmacology (2000) 39 12):2381-2390.
20. Peral A, Navas B, Peláez T, Pintor J: Regulación de la presión intraocular por nucleotides de adenina. Arch Optom (2001) 5:7-14.
21. Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Séguéla P, Voigt M, Humphrey PP: International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev (2001) 53 1):107-118.
22. Pintor J, Peral A: Therapeutic potential of nucleotides in the eye. Drug Dev Res (2001) 52:190-195.
23. Gasull X, Soto D, Peral A, Gual A, Pintor J: Effects of dinucleotides polyphosphates in trabecular meshwork cells and outflow facility invest. Invest Ophthalmol Vis Sci (2004) 45:Abs 5028.
24. Crosson CE, Yates PW, Bhat AN, Mukhin YV, Husain S: Evidence for multiple P2Y receptors in trabecular meshwork cells. J Pharmacol Exp Ther (2004) 309(2):484-489.
25. Pintor J, Díaz-Hernández M, Gualix J, Gómez-Villafuertes R, Hernando F, Miras-Portugal MT: Diadenosine polyphosphate receptors from rat and guinea-pig brain to human nervous system. Pharmacol Ther (2000) 87(2-3 :103-115.